All posts by medical

New test quickly identifies patients whose postoperative pain can be … – EurekAlert

image:A: Giant magnetoresistive (GMR) biosensor array in its reusable cartridge. The black boxed area indicates the region magnified and displayed in B. The red line is inserted for scale. The GMR biosensor is 5 mm in length. B: A zoomed-in image of the GMR biosensor array overlaid with the pattern of functionalized probes on the surface of the individual sensors. The chip hosts an array of 80 individually addressable GMR biosensors, which can be seen in the image as red squares, some of which are covered by the overlaid pattern of probes. Each sensor can be individually functionalized with capture probes and is addressed and measured during readouts for sensor-specific changes in resistance due to the GMR effect. In the pattern used in this study, each single nucleotide polymorphism has both a wild-type (WT) and mutant-type (MT) probe set, as indicated by the matching colors above (dark for WT and light for MT), as well as positive and negative control probes. Six GMR biosensors are dedicated to each probe, for a total of six real-time measurements per probe type. view more

Credit: Dana L. Cortade and Shan X. Wang

Philadelphia, March 14, 2023 Hypnosis is an effective treatment for pain for many individuals but determining which patients will benefit most can be challenging. Hypnotizability testing requires special training and in-person evaluation rarely available in the clinical setting. Now, investigators have developed a fast, point-of-care molecular diagnostic test that identifies a subset of individuals who are most likely to benefit from hypnosis interventions for pain treatment. Their study, in The Journal of Molecular Diagnostics, published by Elsevier, also found that a subset of highly hypnotizable individuals may be more likely to experience high levels of postoperative pain.

Since hypnotizability is a stable cognitive trait with a genetic basis, our goal was to create a molecular diagnostic tool for objectively identifying individuals who would benefit from hypnosis by determining treatability at the point-of-care, explained co-lead investigator Dana L. Cortade, a recently graduated PhD in Materials Science and Engineering, School of Engineering, Stanford University, Stanford, CA, USA. The advancement of nonpharmacological adjuvant treatments for pain is of the utmost importance in light of the opioid epidemic.

Prior research established that the genetic basis for hypnotizability includes four specific single-nucleotide polymorphisms (SNPs), or genetic variations, found in the catechol-o-methyltransferase (COMT) gene for an enzyme in the brain that is responsible for dopamine metabolism in the prefrontal cortex. Although SNPs can contain valuable information on disease risk and treatment response, widespread use in clinical practice is limited because of the complexities, costs, and time delays involved in sending samples to laboratories for testing.

The investigators developed a SNP genotyping assay on a giant magnetoresistive (GMR) biosensor array to detect the optimal combination of the COMT SNPs in patient DNA samples. GMR biosensor arrays are reliable, cheaper, sensitive, and can be easily deployed in point-of-care settings using saliva or blood samples.

The study investigated the association between COMT diplotypes and hypnotizability using a clinical hypnotizability scale called the Hypnotic Induction Profile (HIP) in individuals who had participated in one of the three previous clinical trials in which an HIP was administered. An additional exploratory study of the association between perioperative pain, COMT genotypes, and HIP scores was conducted with the patients in the third cohort, who had undergone total knee arthroplasty (TKA). DNA was extracted from blood samples previously collected in the first cohort, and saliva samples were collected by mail from participants in the other two trials. Participants were considered treatable by hypnosis if they had HIP scores of 3 or higher on a scale of zero to 10.

For participants identified with the optimal COMT diplotypes by the GMR biosensor array, 89.5% scored highly on the HIP, which identified 40.5% of the treatable population. The optimal COMT group mean HIP score was significantly higher than that in the suboptimal COMT group. Interestingly, further analysis revealed that the difference was observed only in women.

Although we had expected some difference in effect between females and males, the association between hypnotizability and COMT genotypes was strongest in the females in the cohort, said co-lead investigator Jessie Markovits, MD, Department of Internal Medicine, Stanford School of Medicine, Stanford, CA, USA. The difference may be due to lower numbers of males in the cohort, or because COMT is known to have interactions with estrogen and to differ in activity by sex. Additional gene targets including COMT, with stratification by sex, could be the focus of future study.

In the exploratory analysis of the relationship between COMT genotypes and pain after TKA surgery, the same optimal COMT individuals had significantly higher postoperative pain scores than the suboptimal group, indicating a greater need for treatment. This supports the body of evidence that COMT genotypes impact pain, and it is also known that COMT genotypes affect opioid use after surgery. Pain researchers can use this technology to correlate genetic predisposition to pain sensitivity and opioid use with response to an evidence-based, alternative remedy: hypnosis, Dr. Cortade said.

COMT SNPs alone are not a complete biomarker for identifying all individuals who will score highly on a hypnotizability scale and experience high pain sensitivity. The GMR sensor nanoarray can accommodate up to 80 SNPs, and it is possible that other SNPs, such as those for dopamine receptors, are needed to further stratify individuals.

The investigators observe that this study highlights the utility and potential of the evolving applications of precision medicine. It is a step towards enabling researchers and healthcare professionals to identify a subset of patients who are most likely to benefit from hypnotic analgesia, Dr. Markovits said. Precision medicine has made great strides in identifying differences in drug metabolism that can impact medication decisions for perioperative pain. We hope to provide similar precision in offering hypnosis as an effective, non-pharmacological treatment that can improve patient comfort while reducing opioid use.

Journal of Molecular Diagnostics

Experimental study

Cells

Point-of-Care Testing of Enzyme Polymorphisms for Predicting Hypnotizability and Postoperative Pain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original post:

New test quickly identifies patients whose postoperative pain can be ... - EurekAlert

Letter for the article Long Term Characteristics of Clinical Distribut … – Dove Medical Press

1Department of Nursing Management, Faculty of Public Health, Universitas Muslim Indonesia, Makassar, Indoensia; 2Department of Biochemistry, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indoensia; 3Department of Internal Medicine, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indoensia

Correspondence: Haeril Amir, Department of Nursing Management, Faculty of Public Health, Universitas Muslim Indonesia, Makassar, Indoensia, Email [emailprotected]

We have read the paper by Wang et al on Long Term Characteristic of Clinical Distribution and Resistance Trends of Carbapenem-Resistant and Extended-Spectrum -Lactamase Klebsiella Pneumoniae Infections.1. We congratulate the authors for providing data in the form of an overview of Klebsiella pneumoniae (KP) infection patterns and KP resistance to several antibiotics, which are useful for the treatment and prevention and control of bacterial infections that are resistant to various antibiotics used in hospitals.

The study conducted by Wang et al showed that carbapenem-resistant KP (CRKP) had the highest proportion of carbapenem-resistant Enterobacteriaceae and most of the infected patients were >60 years old, an increasing trend every year. However, it should be noted that carbapenem resistance is determined when imipenem or meropenem are resistant by antimicrobial susceptibility testing.2 There are several things to be considered, namely virulence factors, drug resistance, and types of KP sequences in different samples to be identified by wire-drawing tests, polymerase chain reactions, drug susceptibility tests, and multi-site sequence typing.3

In the study by Wang et al, they conducted strain identification using the BD PhoenixTM100 system in which the minimum inhibitory concentration of antibiotics was determined by the broth method.1 The method used is appropriate, however we recommend continuing with a modified carbapenem inactivation method in which the isolates studied are determined by multilocus sequence types, and the presence of carbapenemase genes and virulence are examined using the polymerase chain reaction test. In addition, the modified carbapenem inactivation method (mCIM) and the EDTA-carbapenem inactivation method (eCIM) also help to determine the phenotype of the carbapenemase.4 In addition, phenotypic carbapenemase production could also be confirmed by a modified Hodge test, followed by conventional polymerase chain reaction to determine isolates undergoing antibiotic sensitivity test.5

In conclusion, we agree that the level of KP resistance to conventional antibiotics is generally high as well as susceptibility to common antibiotics, especially cefotaxime,1 therefore it is necessary to build a multidisciplinary collaborative mechanism to manage infection and jointly suppress the spread of bacterial resistance. However, with increasing percentage of hypervirulent Klebsiella pneumoniae, the level of antimicrobial resistance of Klebsiella pneumoniae may decrease, therefore we recommend conducting a virulence study of Klebsiella pneumoniae (Shanghai, China) and also creating strategies to combat the persistent challenges created by AMR and developing MDR.5

The authors report no conflicts of interest in this communication.

1. Wang N, Zhan M, Wang T, et al. Long term characteristics of clinical distribution and resistance trends of carbapenem-resistant and extended-spectrum -lactamase Klebsiella pneumoniae infections: 20142022. Infect Drug Resist. 2023;16:12791295. doi:10.2147/IDR.S401807

2. Zhou C, Wu Q, He L, et al. Clinical and molecular characteristics of carbapenem-resistant hypervirulent Klebsiella pneumoniae isolates in a tertiary hospital in shanghai, China. Infect Drug Resist. 2021;14:26972706. doi:10.2147/IDR.S321704

3. Li H-F, Zhang L-X, Zhang W-L, Li J, Y-q L, Hu T-P. Study on virulence genes, drug resistance and molecular epidemiology of Klebsiella pneumoniae with high virulence in inner Mongolia, China. Infect Drug Resist. 2023;Volume 16:11331144. doi:10.2147/IDR.S391468

4. Shen M, Chen X, He J, et al. Antimicrobial resistance patterns, sequence types, virulence and carbapenemase genes of carbapenem-resistant Klebsiella pneumoniae clinical isolates from a tertiary care teaching hospital in Zunyi, China. Infect Drug Resist. 2023;16:637649. doi:10.2147/idr.s398304

5. Gurung S, Kafle S, Dhungel B, et al. Detection of oxa-48 gene in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from urine samples. Infect Drug Resist. 2020;13:23112321. doi:10.2147/IDR.S259967

Original post:

Letter for the article Long Term Characteristics of Clinical Distribut ... - Dove Medical Press

Kayler’s Work Improves Access for Kidney Patients – ubmd.com

Local kidney health activists, transplant recipients and donors met recently at Erie County Medical Center with Liise K. Kayler, MD, clinical professor of surgery and head of the ECMC transplant program, and transplant recipient Barbara Breckenridge, founder of Kidney Health Together,to discuss how to raise awareness about kidney health. From left: Richard Clark, veterans advocate and dialysis patient; Aurelia Keaton, living donor; Esmeralda Sierra, Kidney Health Together board member; Breckenridge; Kayler; Tara Fulgham, dialysis social worker; and Helton Briggs, transplant recipient.

STORY BY ELLEN GOLDBAUM

Of all the organs that can be transplanted, kidneys, by far, are the organ in greatest demand. Kidney failure can take years to develop but there are typically few symptoms until irreparable damage has been done.

After a Transplant, Life Expectancy Doubles

The vast majority of those seeking a kidney transplant are on dialysis. That means that several times a week, individuals must undergo the grueling procedure that does the work that kidneys would normally do, mechanically filtering excess water and waste from the blood.

Less than one-fifth of the 500,000 people in the U.S. currently on dialysis are on the transplant waiting list. And half of the 90,000 patients on the list will die without ever getting a transplant. That reality is all the more devastating in light of this single fact: After a transplant, life expectancy doubles.

As clinical professor of surgery and chief of the Division of Transplant Surgery in the Jacobs School of Medicine and Biomedical Sciences and program director of the Regional Center of Excellence for Transplantation and Kidney Care at Erie County Medical Center, Liise K. Kayler, MD, thinks about that fact every day. She has been laser-focused on how to get more people with end-stage kidney disease transplanted.

Since her arrival, the ECMC transplant program has dramatically improved; the program website states that its kidney transplant waiting times are now some of the shortest in the nation.

But like everyone who works in transplant medicine, Kayler, also a surgeon with UBMD Surgery, was keenly aware of the challenges and cruel ironies that plague kidney transplantation in general. Chief among these is the fact that Black Americans are more than three times as likely as non-Black persons to experience kidney failure but 25% less likely to undergo a transplant, the result of a combination of social and economic disparities.

Kayler saw there were opportunities to make significant improvements.

Standardizing Testing

During the transplant workup period, a patient undergoes a series of medical tests to ensure they are a safe candidate for a transplant. Kayler hired more staff to expedite the requisite testing and standardized the testing so that, wherever possible, it was consistent for all patients.

Brian M. Murray, MD, formerly chief medical officer at ECMC, currently interim chair of the Department of Medicine in the Jacobs School and a physician with UBMD Internal Medicine, explains that Kayler took a comprehensive approach to improving kidney transplant access for all patients.

Dr. Kayler had noticed that the transplant workup period the time from when a patient was referred for transplant to when they were listed for transplant took significantly longer for Black and low-income patients than others, he says. She explored the potential causes for this and suspected that in many cases it was due to social determinants, such as transportation and difficulties accessing care. By assigning patient navigators, the unit was able to improve the speed of workup for all patients.

By 2018, Kayler and her colleagues had built a clinical program that slashed the average time patients spend on the ECMC kidney transplant waiting list. For Black candidates, the number of days spent on the waiting list dropped to 302 from 540.

Dr. Kaylers work has been focused on improving access to transplantable kidneys, both locally and nationwide for patients suffering from advanced chronic renal failure, says Steven D. Schwaitzberg, MD, SUNY Distinguished Professor, chair of the Department of Surgery and president of UBMD Surgery.

Life on dialysis is no picnic, he continues. She is improving the quality of life for many.

Kayler acknowledges these were major improvements. We doubled the rate of timely transplantation for our patients of all races, she says, but if our underserved patients arent at the same level as whites, theres still a disparity.

Kayler conferred with people in UBs Clinical and Translational Science Institute (CTSI) who were experienced in community-based participatory research. Her challenge was to find out how patients with kidney failure could be better empowered to navigate the transplant system. The answer was better patient education through videos and peer mentoring.

We knew that the only way to give culturally tailored information to patients was to have it come from someone like them, Kayler says, someone who knows their challenges.

Such efforts would need to involve health communications, patient education and digital media, skills that arent typically the focus of the training that transplant surgeons go through. It would also require funding, since video animations dont come cheap. Kayler identified an animator, as well as people who did grant writing, so she could explore funding possibilities.

Kayler began holding informal focus groups with patients who provided feedback.

She worked with Thomas Feeley, professor of communication, College of Arts and Sciences, who studies campaigns promoting organ donation. Together, they applied for and were awarded a $1.3 million grant from the Health Research Services Administration of the U.S. Department of Health and Human Services. The grant funded a pilot test of videos designed to improve what patients knew about kidney transplant and about getting a kidney from a live donor.

Focus on Live Kidney Donation

Noting that only 6,000 live kidney donations happen every year in the U.S., the focus on live donor kidney transplantation is critical, Kayler notes. Boosting that number could help solve the donor shortage, she says. Low rates of live donor kidney transplantation are largely the result of knowledge gaps and misperceptions about it among patients and members of their social networks.

The intervention Kayler and Feeley developed in collaboration with community input was a series of two-minute animated videos made for sharing called KidneyTIME. The results were more than promising: 98% of the transplant candidates and their social network members found KidneyTIME informative and engaging; at three weeks follow-up, 77% had viewed it again on their own device and 63% had shared it.

But to truly understand whether the videos were having the intended effect, Kayler knew she needed to compare two groups of patients: one that was exposed to the videos and one that was exposed to the patient education that was the current standard of care. She needed to apply to the NIH to fund a randomized clinical trial.

After months of extensive rewriting and revising, the grant application was finally submitted. In August 2021, NIH awarded Kayler $3.6 million. It was funded on the first try.

The grant was a major boost: It would pay for the testing of the videos and dissemination to the community. Kayler knew it was time to add the perspective that as a surgeon she could never provide that of someone whos gone through a transplant.

She thought immediately of Barbara Breckenridge, a passionate patient advocate, founder of the Kidney Foundation of Western New York and a true kidney transplant success story: It has been more than two decades since her kidney transplant in July 1999.

Living a Normal Life

When I was transplanted with a kidney from a deceased donor, they told me I might get five to seven more years, Breckenridge says. And here I am with 23 years. Patients just need to see somebody who has been transplanted who is living a normal life, so they can say, well if she can do it, I can do it.

In 2021, Kayler and Breckenridge were awarded a seed grant from UBs CTSI to create a community advisory board specifically targeting improved transplantation among Black patients. Established during the pandemic, the board, composed of Kayler, Breckenridge, patients, caregivers, donors and a social worker, meets monthly, mostly on Zoom. The members are passionately united in their goal of promoting kidney transplant for Black patients.

The primary focus is to identify barriers to kidney transplant for Black patients and to brainstorm potential solutions. They are launching a peer mentoring effort so that Black transplant recipients can directly educate other Black patients who are considering a transplant.

But the members, so well versed in the needs of the patients, have found other ways to serve as well. Breckenridge createdKidney Health Together, a volunteer-run, 501c3 organization whose mission is to help kidney patients in Western New York live healthier lives. It operates the Healthy Living Pantry, which provides healthy food choices for kidney patients experiencing food emergencies. Many of these patients are in low socioeconomic groups and cannot work.

The connections that Kayler and her teams, consisting of both hospital staff and community members, have established and nurtured are a result of the commitment that she brought with her to Buffalo and that has been intensifying ever since.

In spite of the many challenges, Kayler says she finds transplant surgery the most fulfilling type of surgery she could do.

I want everybody to be able to get a kidney transplant as soon as possible, she says. I chose transplant surgery because it saves the lives of people who are on the brink of dying, some of whom had given up hope. With every transplant we do, everyone is happy and hopeful the patient, the family, the transplant team, even the hospital leadership.

Its a celebration of life.

Visit link:

Kayler's Work Improves Access for Kidney Patients - ubmd.com

More than 30,000 European and international endocrinologists urge Brussels to take action on REACH revision – Newswise

Newswise A broad coalition of over 30,000 European and international endocrine experts have today called on EU legislators to publish the revised REACH proposal without any further delay and no later than June 2023.

Citing the urgent and immediate need to minimise exposure to Endocrine Disrupting Chemicals (EDCs) in the interest of public health, the experts insist that flaws in the REACH regulation must be addressed without delay. EDCs are not a compromise area, and extending the current legislation is required to fulfill the mentioned objectives.

The petition was launched by the Endocrine Society, the European Society of Endocrinology (ESE), and 42 European national and specialist endocrine societies represent the European and international endocrine research and clinical community. The petition has been submitted to the European Commission.

The experts are extremely concerned that the current REACH regulation does not effectively address the numerous health impacts stemming from EDC exposure. The necessary steps to reduce exposure to hazardous EDCs and establish lasting protection for human health can only come in a revision of REACH itself.

EDCs are not an area for compromise. An immediate and rigorous revision and extension to the current legislation is needed to effectively address the many current adverse health impacts. Any further delay is unacceptable.

In addition to the huge impact on human and ecological health, EDCs are also linked to massive economic costs borne by EU citizens: conservative estimates have linked EDC exposures to some157 billion in additional health care costs and lost earnings.

EDCs, which include bisphenols, phthalates, and PFAS, among other chemicals in commerce, are pervasive and linked to serious adverse effects on endocrine systems leading to diseases such as infertility, diabetes, cancer, and altered neurological development. Health impacts from EDC exposures are widespread and cause suffering throughout the European Union. Moreover, individuals such as pregnant women and children are uniquely susceptible to the effects of endocrine disruption, meaning that action now can prevent harm to current and future generations.

Go here to read the rest:

More than 30,000 European and international endocrinologists urge Brussels to take action on REACH revision - Newswise

Over 1500 healthcare professionals attend 7th Qatar Diabetes … – The Peninsula

Delegates attend a session during the Seventh Qatar Diabetes, Endocrinology, and Metabolic Conference (QDEM-7).

Doha: More than 1500 healthcare professionals attended the Seventh Qatar Diabetes, Endocrinology, and Metabolic Conference (QDEM-7) which was hosted by Hamad Medical Corporations (HMC) Endocrine and Diabetes Division, Department of Medicine, and the Qatar Metabolic Institute (QMI).

The conference, held in person and online with attendees and speakers from around the world, brought together local and international experts in the fields of endocrinology, obesity, and diabetes to discuss the latest research, treatments, technological advances, and preventative measures for these conditions.

The event also incorporated the 2nd Qatar Diabetes and Obesity Research Symposium a flagship activity of the National Diabetes Strategy, 2016-2022, and intends to promote diabetes and obesity research in Qatar.

World-renowned international, regional and local speakers presented and updated delegates on a diverse range of topics including non-alcoholic fatty liver disease; Pediatric Endocrinology; Perimenopausal management; Neuroendocrine disorders and calcium and electrolytes disorders

Dr. Mahmoud Ali Zirie, Chair of the Conferences Organizing Committee and Head of HMCs Endocrinology and Diabetes Division, said the conference provided an opportunity to share the work being done here in Qatar and to deliver improvements tailored to the local population.

This year our program focused on a range of important and emerging areas including diabetes and obesity in pediatric patients and the latest technologies available, Dr. Zirie said. Its more important than ever that healthcare professionals have access to the most up-to-date research and information about diabetes, endocrinology and metabolic medicine.

Professor Abdul Badi Abou Samra, Director of Qatar Metabolic Institute, said the event provided an important platform for frontline clinicians, scientists, and researchers to discuss strategies and approaches for the management and prevention of diabetes and associated conditions.

Diabetes is a complex condition which can lead to debilitating long-term complications and acute illness. The disease in Qatar is quite prevalent with about 17 percent of Qatars adult population thought to have diabetes. About 20 percent of Qatars population is estimated to be pre-diabetic, he said.

Dr. Ibrahim Al Janahi, Chair of the Scientific Committee and Senior Consultant in Endocrine and Diabetes Division said many diabetics live with other associated complications such as high blood pressure, kidney disease, and vision impairment which require additional consideration.

It is important for the local and international medical community to meet and discuss trends, best practice, and long-term strategies for the prevention and mitigation of complications related to this disease so we can continue to provide the best care for our patients, Dr. Al Janahi said.

Among the speakers at this years event were Dr. Richard Quinton is a Consultant Endocrinologist at the Royal Victoria Infirmary, Newcastle-upon-Tyne, UK; Marius N. Stan, M.D., consultant in endocrinology at Mayo Clinic and Martin Savage is Emeritus Professor of Pediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London.

Excerpt from:

Over 1500 healthcare professionals attend 7th Qatar Diabetes ... - The Peninsula

Age- and sex-specific values needed to avoid subclinical thyroid … – Healio

March 14, 2023

2 min read

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Back to Healio

Providers should use age- and sex-specific reference ranges to diagnose subclinical hypothyroidism or hyperthyroidism, especially for older adults, according to a study published in Thyroid.

These data clearly demonstrate the clinical relevance of using age- and sex-specific values, particularly serum thyroid-stimulating hormone levels, when diagnosing subclinical hypothyroidism, Masanobu Yamada, MD, PhD, assistant professor in the department of internal medicine, division of endocrinology and metabolism at Gunma University Graduate School of Medicine in Japan, and colleagues wrote. We found a high rate of overdiagnosed subclinical hypothyroidism, especially in those aged 60 years and older. Although it is a low rate, patients with subclinical hyperthyroidism were underdiagnosed, particularly in middle-aged men and women.

Researchers analyzed health records for 22,992 adults who underwent annual checkups at Takasaki Hidaka Hospital in Japan and 515 euthyroid adults who visited Okamoto Thyroid Clinic in Japan. Of those who visited Takasaki Hidaka Hospital, 14,860 had thyroid function evaluated using a Siemens test kit from 2006 to 2013, and 8,132 had thyroid function evaluated using an Abbott test kit from 2020 to 2022. The Okamoto Thyroid Clinic used kits from Toso to analyze thyroid function from 2016 to 2019.

Subclinical hypothyroidism was defined as elevated serum TSH with normal free thyroxine, and subclinical hyperthyroidism was defined as low serum TSH with normal free T4. The researchers estimated age- and sex-specific reference ranges based on TSH and free T4 measurements and compared them with the manufacturer reference ranges for all three tests.

Using the Siemens test kit, median serum TSH was 1.5 mIU/L for women aged 30 to 39 years and gradually increased with age to 1.9 mIU/L for women aged 60 to 69 years. Men aged 30 to 39 years had a median TSH of 1.4 mIU/L with an increase with age to 1.6 mIU/L for those aged 60 to 69 years. Similar increases were observed for adults tested with the Abbott kit.

Serum free T4 levels were constant with age for women using all three test kits. Men had higher free T4 levels than women and had a gradual decrease with age when using all three kits.

Using the Abbott test kit, median serum free triiodothyronine was 3.26 pg/mL for men aged 30 to 39 years and declined to 3.11 pg/mL for men aged 60 to 69 years. Levels were higher for men compared with women of the same age. Similar findings were observed using the Toso test kit.

About half of women aged 30 to 39 years who were classified as having subclinical hypothyroidism using manufacturer reference ranges had normal thyroid function when age- and sex-specific reference ranges were used. The proportion of overdiagnosed adults increased with age, with 78% of women aged 60 to 69 years classified as having subclinical hypothyroidism being reassessed with normal thyroid function using age- and sex-specific recommendations.

Overdiagnosis was less common for younger men, with no men aged 30 to 39 years and about 5% of those aged 40 to 49 years reclassified with normal thyroid function using age- and sex-specific cutoffs. However, about 62% of men aged 60 to 69 years diagnosed with subclinical hypothyroidism using manufacturer reference ranges were reclassified as having normal thyroid function using age- and sex-specific reference ranges.

The researchers acknowledged several limitations with the study, including a lack of data on adults younger than 30 years or older than 70 years, as well as the potential that reference ranges may be influenced by ethnicity in other countries.

Our findings should therefore be validated in future studies including other racial and ethnic groups, as the prevalence of autoimmune disease may differ according to ethnicity and the geographic location, the researchers wrote.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Back to Healio

Excerpt from:

Age- and sex-specific values needed to avoid subclinical thyroid ... - Healio

Family’s participation key to advancing diabetes research | VUMC … – VUMC Reporter

When half of their six children were diagnosed with what was then believed to be Type 1 diabetes, David and Ellen Pursell decided their family would participate in research related to the health condition. This family photo from several years ago includes, seated, from left, Peggy, Ramsey and Chrissy. Standing, from left, are Vaughan, Ellen, Martin, David and Parker.

by Jill Clendening

Individuals with Type 1 diabetes have a smaller pancreas than people without diabetes. This is surprising because the pancreatic islets and their insulin-producing beta cells account for just a small fraction of the pancreas, so the loss of beta cells in Type 1 diabetes would not be expected to reduce pancreas size.

Now, a study of one family from Alabama has led Vanderbilt University Medical Center researchers to discover that insulin deficiency, independent of the autoimmunity associated with Type 1 diabetes, is the principal factor leading to a markedly smaller pancreas.

Four members of this family of eight have monogenic diabetes from a rare mutation in the insulin gene, leading to insulin deficiency without autoimmunity. Magnetic resonance imaging (MRI) of the pancreas showed a reduced size and altered shape in the individuals with diabetes. This reduction in size was similar to what had previously been observed in individuals with Type 1 diabetes. These new findings are published in Diabetes Care, a journal of the American Diabetes Association.

While persons with Type 1 diabetes typically have multiple genes that are known to contribute to the development of the autoimmune disorder, individuals with a single mutation that only impacts the insulin gene provided the investigators a unique opportunity to examine the impact of that single factor on pancreas size.

This is a wonderful story about the power of a single family to inform us about the process of a disease that affects millions of people, said Daniel Moore, MD, PhD, associate professor of Pediatrics in the Ian Burr Division of Pediatric Endocrinology and Diabetes. There are not many families, especially not large families, who are known to have exactly this form of diabetes, who could come forward to help us answer this question. But they responded to the call, and theyve provided a really clear answer to a very fundamental biologic question.

About two decades ago, David Pursell and his wife, Ellen, agreed that he and three of their six children who were diagnosed with diabetes would participate in research with the hope more could be learned about the disease. It was as simple as giving a little blood.

They were surprised years later when a researcher from the University of Chicagos Kovler Diabetes Center called to tell them that advances in science had revealed that the four actually had monogenic diabetes due to a mutation in the insulin gene instead of Type 1 diabetes.

Their care remained the same daily monitoring of their blood glucose and multiple doses of insulin each day.

Several more years went by before science came knocking again. Last year, the Pursells were contacted by a team of VUMC researchers who were collaborating with Siri Greeley, MD, PhD, and colleagues at the Kovler Diabetes Centers Monogenic Diabetes Registry at the University of Chicago. The Vanderbilt research team asked if the family could travel to Nashville to have precise measurements of their pancreas taken at the Medical Center.

The VUMC research team, which includes Moore, Jordan Wright, MD, PhD, Jon Williams, PhD, Melissa Hilmes, MD, and Alvin C. Powers, MD, along with colleague Jack Virostko, PhD, at The University of Texas at Austin, had previously found the reduction in pancreas size was present at the time of Type 1 diabetes diagnosis. The Vanderbilt investigators had also organized an international team, the Multicenter Assessment of the Pancreas in Type 1 Diabetes, to develop a standardized MRI imaging protocol to assess pancreas volume and microarchitecture.

We know the pancreas is much smaller in individuals with Type 1 diabetes, but there havent been good models to understand exactly whats going on, said Jordan Wright, MD, PhD, an instructor in the Division of Diabetes, Endocrinology and Metabolism and first author on the manuscript.

One hypothesis is that the autoimmune process of Type 1 diabetes also affects the exocrine part of the pancreas. This is the first time we can actually demonstrate in humans that insulin is a major factor in determining pancreas size and the loss of it leads to a much smaller pancreas.

David and Ellen and their now adult children, Peggy Rice, Vaughan Spanjer, Chrissy Adolf, Ramsey Nuss, and twin sons Parker and Martin Pursell, each had their pancreas size measured using the standardized Vanderbilt MRI protocol. David, Chrissy, Parker and Martin have monogenic diabetes; the rest of the family does not.

When we talked to some of the doctors at Kovler in Chicago, they asked if wed be interested in participating in some trials or research and we said, Of course, anything we can do, said David Pursell. Part of it, Ill admit, was selfish. When we learned our diabetes was not caused by an immune response due to our islet cells being attacked by antibodies, then we thought maybe weve got the chance of getting an islet cell transplant.

But also, were obviously all in this together. If, by virtue of our family volunteering for this research we can help anyone else, we felt like it would be worth it.

The Vanderbilt investigators, as part of MAP-T1D, are building on this study by measuring pancreas size in individuals at known risk of developing diabetes and correlating those measurements with the imminence of a diabetes diagnosis. They also are examining whether reduced pancreas size correlates with other issues such as the need for pancreatic enzymes to support digestion.

This research was performed with assistance from the Vanderbilt University Institute of Imaging Sciences (National Institutes of Health [NIH] project 1S10OD021771-01), the Vanderbilt Institute for Clinical and Translational Research (UL1-TR000445) and the Institute for Translational Medicine (UL1-TR000430) and with the support of the Leona M. and Harry B. Helmsley Charitable Trust, the Juvenile Diabetes Research Foundation, the Doris Duke Charitable Foundation, the NIH (DK104942, DK129979) and the Vanderbilt and Chicago Diabetes Research and Training Centers (DK20593, DK20595).

View post:

Family's participation key to advancing diabetes research | VUMC ... - VUMC Reporter

Endocrine Society supports EPA rule regulating forever chemicals … – Newswise

Newswise WASHINGTONThe Endocrine Society supports a new U.S. Environmental Protection Agency (EPA) rule which includes provisions to regulate several per- andpolyfluoroalkyl substances (PFAS)including PFOA and PFOSfound in our drinking water.

The proposed regulation sets an aggressive limit for these PFAS and their mixtures and acknowledges effects at extremely low levels by proposing a health based Maximum Contaminant Level Goal (MCGL) of zero. This is the first time the government has regulated a new chemical in drinking water in more than 30 years.

The new rule would require major water treatment upgrades at utilities across the country.

PFAS are manmade chemicals used as oil and water repellents and coatings for common products including cookware, carpets and textiles. PFAS chemicals can contaminate drinking water supplies near facilities where the chemicals are used.

Theseendocrine-disrupting chemicalsdo not break down when they are released into the environment, and they continue to accumulate over time. They pose health dangers at incredibly low levels and have been linked to endocrine disorders such as cancer, thyroid disruption and reproductive difficulties.

While this rule makes important progress towards reducing PFAS in drinking water to improve public health, continued vigilance and a more comprehensive class-based approach will remain necessary as PFAS comprise a large and complex class of chemicals.

# # #

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the worlds oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site atwww.endocrine.org. Follow us on Twitter at@TheEndoSocietyand@EndoMedia.

See more here:

Endocrine Society supports EPA rule regulating forever chemicals ... - Newswise

American Society for Clinical Investigation honors physician … – Washington University School of Medicine in St. Louis

Visit the News Hub

3 early-career scientists recognized for achievements in research at WashU

Three physician-scientists whose research occurred at Washington University School of Medicine in St. Louis have been honored with the Young Physician-Scientist Award by the American Society for Clinical Investigation. From left, they are Abby Margaret Green, MD; Parker C. Wilson, MD, PhD; and Jing Hughes, MD, PhD.

Three early-career scientists who have conducted their research at Washington University School of Medicine in St. Louis have been honored with the Young Physician-Scientist Award by the American Society for Clinical Investigation (ASCI). They are Abby Margaret Green, MD; Jing Hughes, MD, PhD; and Parker C. Wilson, MD, PhD.

The honor recognizes 50 physician-scientists nationwide who are early in their careers and have had notable achievements in their research. The award supports their involvement with three scientific associations offering leadership development workshops, panel discussions with ASCI members, virtual poster sessions and other career-enhancing activities.

Green, an assistant professor of pediatrics and of pathology & immunology, focuses on the causes of genetic mutations associated with pediatric and adult-onset cancers. She studies how specific enzymes, which cause damage to DNA, promote the development and progression of cancer. The goal of her research is to develop targeted therapies for cancer. In the process, Greens lab emphasizes mentorship. She is affiliated with Siteman Cancer Center and Siteman Kids, and the Roy and Diana Vagelos Division of Biology & Biomedical Sciences.

Hughes, an assistant professor of medicine in the Division of Endocrinology, Metabolism & Lipid Research, studies pancreatic cells that produce hormones that drive glucose metabolism, a key factor in processing and storing energy in the body. Type 1 and Type 2 diabetes can result when glucose levels are too high. Specifically, she analyzes the role in diabetes of an organelle called the primary cilium. Hughes is funded by the National Institutes of Health (NIH) and has established collaborations with other scientists to study the structure and function of pancreatic cells.

Wilson formerly an assistant professor in the Division of Anatomic and Molecular Pathology within the Department of Pathology & Immunology, and the universitys Institute of Clinical and Translational Sciences researches single cell biology and the genetics of kidney disease. Previously, Wilson was a fellow in WashUs Molecular Genetic Pathology program. Earlier this year, he accepted a tenure-track position at the University of Pennsylvania; however, the award recognizes his research conducted at Washington University.

For more information on the awards, please visit ASCI.

Read the original:

American Society for Clinical Investigation honors physician ... - Washington University School of Medicine in St. Louis